APYX News and Press, Apyx Medical Corporation From 02/27/23

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA...

Helium plasma and radiofrequency technology company Apyx Medical ( NASDAQ: APYX ) and units have entered into a five-year secured credit facility with the specialty finance firm, MidCap Financial. The agreement helps APYX secure an up to $35M facility consisting of senior, secured ter...

Facility includes a senior, secured term loan of up to $25 million and a revolving line of credit of up to $10 million Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and s...

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the fourth quarter and fiscal year 2022 will be released befo...

RENUVION® COSMETIC NECK LAXITY PROCEDURE TO BE FEATURED ON 'THE BALANCING ACT' TALK SHOW ON LIFETIME® FEBRUARY 13 PR Newswire Episode to Feature Beverly Hills Plastic Surgeon Dr. Charles J. Galanis Performing Renuvion's Minimally Invasive Neck Procedure ...

Apyx Medical ( NASDAQ: APYX ) said it submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for expanded use of Renuvion APR Handpiece. The company is seeking to include a specific indication for the use of Renuvion for coagulation of subcu...

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has submitted a 510(k) premarket notification (“510(k) submission”) for...

APYX MEDICAL CORPORATION LAUNCHES NEW 'APYX ONE CONSOLE' FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATES PR Newswire FDA-Cleared, All-in-One Advanced Energy System Now Available for Medical Professionals CLEARWATER, Fla. , Jan. 25, 2023 ...

Apyx Medical ( NASDAQ: APYX ) has reported preliminary revenue results for the Q4 and FY22. Q4 total revenue is anticipated to be in a range of $12.1M to $12.5M, representing a decline of 28% to 26% Y/Y, vs consensus of $13.36M . Q4 Advanced Energy revenue in a range of $1...

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2022. ...